Kelm Matthew
ASHP Global Consulting Services 4500 East-West Highway, Suite 900, Bethesda, MD 20814, United States of America.
Explor Res Clin Soc Pharm. 2022 Jul 13;7:100157. doi: 10.1016/j.rcsop.2022.100157. eCollection 2022 Sep.
Unit-dose packaging systems are widely used and accepted practices in many hospitals in the US. When adopting a unit-dose, there are three different avenues in which pharmaceuticals can be obtained. Products can be purchased from a manufacturer-produced source, outsourced to repackaging by a 3rd-party repackaging service or repackaged in-house by investing in the technology and the resources to do so. Prior literature has suggested that manufacturer-based unit-dose purchasing was associated with a 1% cost savings over repackaged unit-dose. In this study, we hope to take a more extensive look at the cost and concerns associated specifically with unit dose liquids when purchased from a manufacturer, outsourced to a third party repackager, or repackaged from bulk bottles with in-house technology and resources.
A cost evaluation model, which factored in cost associated with used and expired product, was utilized to estimate and compare the cost of the three systems.
Overall cost between the three systems was largely similar, although manufacturer-based repackaging was determined to be the most cost effective system.
The results of this decision model analysis suggests that the cost associated with purchasing unit dose liquids from manufacturers, third party repackagers, and in-house repackaging are similar. Therefore, utilizing a specific system is unlikely to make a significant impact on the overall pharmaceutical budget for a large hospital or health system.
单剂量包装系统在美国许多医院中被广泛使用且是被认可的做法。采用单剂量时，有三种不同途径可获取药品。产品可从制造商生产源采购，外包给第三方重新包装服务进行重新包装，或通过投资技术和资源在内部进行重新包装。先前的文献表明，基于制造商的单剂量采购比重新包装的单剂量节省1%的成本。在本研究中，我们希望更全面地审视从制造商处购买、外包给第三方重新包装商或使用内部技术和资源从大包装瓶重新包装单剂量液体时的成本及相关问题。
使用一个考虑了与使用过和过期产品相关成本的成本评估模型来估计和比较这三种系统的成本。
尽管基于制造商的重新包装被确定为最具成本效益的系统，但这三种系统的总体成本在很大程度上相似。
该决策模型分析的结果表明，从制造商、第三方重新包装商以及内部重新包装采购单剂量液体的相关成本相似。因此，对于大型医院或医疗系统而言，采用特定系统不太可能对总体药品预算产生重大影响。
